VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

vebreltinib (APL-101) - Apollomics

http://www.ncbi.nlm.nih.gov/pubmed/42376809

Binghao Li; Hao Qu; Hengyuan Li; Meng Liu; Nong Lin; Peng Lin; Xiaobo Yan; Xin Huang; Xiumao Li; Yaling Jiang; Zhaoming Ye

Jul 1, 2026